ENTRIES TAGGED "FDA"

Synthetic biology on the cusp

Oliver Medvedik on the grassroots future of biohacking and the problems with government overreach.

BioCoder image plants in dish with tweezersWhither thou goest, synthetic biology? First, let’s put aside the dystopian scenarios of nasty modified viruses escaping from the fermentor Junior has jury-rigged in his bedroom lab. Designing virulent microbes is well beyond the expertise and budgets of homegrown biocoders.

“Moreover, it’s extremely difficult to ‘improve’ on the lethality of nature,” says Oliver Medvedik, a visiting assistant professor at The Cooper Union for the Advancement of Science and Art and the assistant director of the Maurice Kanbar Center for Biomedical Engineering. “The pathogens that already exist are more legitimate cause for worry.” Read more…

Comments: 2

The Amazon whisperer, invisible interfaces, FDA vs 23andMe, and robots usher in a new polical order

A backchannel look at what's on our radar.

The Radar team does a lot of sharing in the backchannel. Here’s a look at a selection of stories and innovative people and companies from around the web that have caught our recent attention. Have an interesting tidbit to contribute to the conversation? Send me an email or ping me on Twitter

Comment: 1

23andMe flap at FDA indicates fundamental dilemma in health reform

We must go beyond hype for incentives to provide data to researchers

The FDA order stopping 23andM3 from offering its genetic test kit strikes right into the heart of the major issue in health care reform: the tension between individual care and collective benefit. Health is not an individual matter. As I will show, we need each other. And beyond narrow regulatory questions, the 23andMe issue opens up the whole goal of information sharing and the funding of health care reform.

Read more…

Comments: 2

Games for Health covers current status of behavior change

There have never been better reasons for doing right by ourselves

A few existing and upcoming projects that illustrate what games are doing in health care, and some trends to watch.

Comment: 1

Recombinant Research: Breaking open rewards and incentives

Can open data dominate biological science as open source has in software?

To move from a hothouse environment of experimentation to the mainstream of one of the world's most lucrative and tradition-bound industries, Sage Bionetworks must aim for its nucleus: rewards and incentives. Comparisons to open source software and a summary of tasks for Sage Congress.

Comment

Recombinant Research: Sage Congress plans for patient engagement

The Vioxx problem is just one instance of the wider malaise afflicting the drug industry. Managers from major pharma companies expressed confidence that they could expand public or "pre-competitive" research in the direction Sage Congress proposed. The sector left to engage is the one that's central to all this work–the public.

Comment

OSCON preview: Shahid N. Shah on medical devices and open source

Connecting medical devices to electronic health record systems, and the roles of open source software, regulation, and clinical improvement.

Comments Off